These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 31432)

  • 21. A critical assessment of behavioural test procedures used to analyse dopaminergic and antidopaminergic drugs.
    Nohria V
    Methods Find Exp Clin Pharmacol; 1983; 5(6):357-64. PubMed ID: 6137599
    [No Abstract]   [Full Text] [Related]  

  • 22. D2 dopamine antisense RNA expression vector, unlike haloperidol, produces long-term inhibition of D2 dopamine-mediated behaviors without causing Up-regulation of D2 dopamine receptors.
    Davidkova G; Zhou LW; Morabito M; Zhang SP; Weiss B
    J Pharmacol Exp Ther; 1998 Jun; 285(3):1187-96. PubMed ID: 9618422
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of a single administration of buspirone on catalepsy, yawning and stereotypy in rats.
    Conceição IM; Frussa-Filho R
    Braz J Med Biol Res; 1993; 26(1):71-4. PubMed ID: 8220270
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interactions between D1 and D2 dopamine receptor family agonists and antagonists: the effects of chronic exposure on behavior and receptor binding in rats and their clinical implications.
    Braun AR; Laruelle M; Mouradian MM
    J Neural Transm (Vienna); 1997; 104(4-5):341-62. PubMed ID: 9295170
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of buspirone on dopaminergic supersensitivity.
    Queiroz CM; Frussa-Filho R
    Life Sci; 1997; 61(4):371-82. PubMed ID: 9244363
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of 1,3-di-o-tolylguanidine and rimcazole, selective sigma ligands, on apomorphine and neuroleptic effects.
    Maj J; Rogóz Z; Skuza G
    Pol J Pharmacol; 1993; 45(3):327-30. PubMed ID: 8106091
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of apomorphine-induced behaviors by derivatives of 2-amino-1, 2, 3, 4-tetrahydronaphthalene.
    Rusterholz DB; Long JP; Flynn JR; Glyn JR; Barfknecht CF; Lind RW; Johnson AK
    Arch Int Pharmacodyn Ther; 1978 Apr; 232(2):246-60. PubMed ID: 567044
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
    Chipkin RE; Iorio LC; Coffin VL; McQuade RD; Berger JG; Barnett A
    J Pharmacol Exp Ther; 1988 Dec; 247(3):1093-102. PubMed ID: 2905002
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of dexfenfluramine on dopamine dependent behaviours in rats.
    Thorat VM; Gaonkar RK; Bhosale KB; Balsara JJ
    Indian J Physiol Pharmacol; 2005 Jan; 49(1):39-48. PubMed ID: 15881857
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Behavioral effects of chronic apomorphine, and D-1/D-2 dopamine receptor activities in rats].
    Minematsu N
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1995 Jun; 15(3):247-52. PubMed ID: 7584718
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Central action of narcotic analgesics. I. Catalepsy and stereotypy in rats and narcotic analgesics.
    Malec D; Fidecka S; Langwiński R
    Pol J Pharmacol Pharm; 1977; 29(3):177-93. PubMed ID: 560683
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of angiotensin on the central action of dopamine.
    Braszko J; Wiśniewski K
    Pol J Pharmacol Pharm; 1976; 28(6):667-72. PubMed ID: 1034924
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effect of (+/-)12-chloroscoulerine on brain dopamine receptors].
    Chen LJ; Xi Y; Pang DW; Zhou QT; Jin GZ
    Zhongguo Yao Li Xue Bao; 1996 Mar; 17(2):185-9. PubMed ID: 9772676
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alpha 1-adrenoceptor blocking properties of spiroxatrine in rat aorta.
    Terrón JA; Ransanz V; Ibarra M; Hong E; Villalón CM
    Life Sci; 1992; 51(1):PL1-6. PubMed ID: 1352025
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure--activity relationships of n-substituted dopamine and 2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene analogues: behavioral effects in lesioned and reserpinized mice.
    Ginos JZ; Stevens JM; Nichols DE
    J Med Chem; 1979 Nov; 22(11):1323-9. PubMed ID: 574901
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist. II: Behavioral profile predictive of an atypical antipsychotic activity.
    Depoortere R; Boulay D; Perrault G; Bergis O; Decobert M; Françon D; Jung M; Simiand J; Soubrié P; Scatton B
    Neuropsychopharmacology; 2003 Nov; 28(11):1889-902. PubMed ID: 12902993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Some behavioural effects of chloroquine in rats suggesting dopaminergic activation.
    Amabeoku GJ
    Indian J Med Res; 1994 Feb; 99():87-94. PubMed ID: 8005645
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The influence of insulin hypoglycemia on central dopaminergic structures of the rat.
    Kleinrok Z; Ossowska G; Stelmasiak M; Juszkiewicz M
    Pol J Pharmacol Pharm; 1983; 35(6):489-95. PubMed ID: 6377282
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of piracetam, a cyclic GABA analogue, on haloperidol-induced catalepsy in the rat.
    Balsara JJ; Bapat TR; Chandorkar AG
    Indian J Physiol Pharmacol; 1980; 24(3):227-32. PubMed ID: 7193183
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of daily chlorpromazine administration on behavioural and physiological parameters in the rat.
    Nsimba SE
    Indian J Physiol Pharmacol; 2009; 53(3):209-18. PubMed ID: 20329367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.